{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:28:52Z","timestamp":1787801332722,"version":"build-2784847793"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy and safety of intravenous (IV) secukinumab in patients with active psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>INVIGORATE\u20102 (NCT04209205) was a randomized, placebo\u2010controlled, phase 3 trial. Patients with active PsA were randomized 1:1 to receive IV secukinumab (6 mg\/kg at baseline followed by 3 mg\/kg every four weeks [q4w]) or placebo. At week 16, patients randomized to placebo were switched to IV secukinumab (3 mg\/kg q4w), and patients who received IV secukinumab continued treatment through week 52. The primary efficacy endpoint was achievement of 50% improvement in American College of Rheumatology response criteria (ACR50) at week 16. Efficacy and safety were evaluated through weeks 52 and 60, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 191 patients randomized to IV secukinumab and 190 to placebo\/IV secukinumab, 177 (92.7%) and 170 (89.5%) completed the entire study period, respectively. A significantly higher proportion of patients who received IV secukinumab versus placebo achieved ACR50 at week 16 (31.4% vs 6.3%; adjusted\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). All secondary efficacy endpoints were met at week 16 (all adjusted\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05 using the predefined hypothesis\u2010testing hierarchy). Patients who switched from placebo to secukinumab at week 16 showed rapid improvements in ACR50 rates; by week 52, both treatment arms experienced similar improvements in efficacy outcomes. No new or unexpected safety signals were observed with receiving IV secukinumab. One death was reported in the placebo group before week 16.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IV secukinumab led to rapid and sustained improvements in clinical measures of PsA, and the safety profile was consistent with that of secukinumab administered subcutaneously.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.42997","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T23:34:46Z","timestamp":1726788886000},"page":"171-179","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo\u2010Controlled Phase 3 Study"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"first","affiliation":[{"name":"Altoona Center for Clinical Research  Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Sedova","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology and Charles University in Prague  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Churchill","sequence":"additional","affiliation":[{"name":"Arthritis Center of Nebraska  Lincoln"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Kotha","sequence":"additional","affiliation":[{"name":"Sharp Community Medical Group  La Mesa California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Singhal","sequence":"additional","affiliation":[{"name":"SouthWest Arthritis Research Group  Mesquite Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Torres","sequence":"additional","affiliation":[{"name":"Highlands Advanced Rheumatology and Arthritis Center  Avon Park Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"Integral Rheumatology &amp; Immunology Specialists  Plantation Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Whelan","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dumortier","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19144.1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1431921"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107925"},{"key":"e_1_2_7_7_1","volume-title":"Cosentyx\u00ae (Secukinumab) [prescribing information]","year":"2023"},{"key":"e_1_2_7_8_1","volume-title":"Cosentyx: Summary of Product Characteristics","author":"European Medicines Agency"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0163-5"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22552"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23537"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez420"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30564-X"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S242336"},{"key":"e_1_2_7_25_1","first-page":"408","article-title":"Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis","volume":"11","author":"Xu Y","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00436-x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S121032"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:38:38Z","timestamp":1759934318000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/art.42997"],"URL":"https:\/\/doi.org\/10.1002\/art.42997","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"2024-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}